Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hannele Ruohola-Baker has a total of 823 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrin-independent Tie2 activation using de novo designed proteins

    by Clara McCurdy, Yan Ting Zhao, Saurav Kumar, Brian Coventry, Anne Pink, Yaoyao Fu, Phil Bohn, Siyu Zhu, Inna Goreshnik, Xinru Wang, et al.

    The Angiopoietin–Tie2 pathway is a key regulator of vascular stability, but therapeutic exploitation has been limited by the poor developability of Angiopoietin-1 (Ang1), and there are key unresolved mechanistic questions. Ang1 binds both Tie2 and α5β1 integrin, and the role of the α5β1 interaction in signaling has been unclear. We used RFdiffusion to design a stable, high-affinity Tie2 minibinder that has no affinity for α5β1. The binder is a selective antagonist in monomeric form, and a potent agonist when assembled into an octavalent architecture (H8mb) which drives Tie2 clustering. H8mb signals as potently as Ang1, indicating that integrin engagement is not required for Tie2 activation. However, the duration of signaling is reduced, and internalization of H8mb-Tie2 complexes is more rapid, suggesting that integrin may function as a co-receptor for Ang1 that prolongs signaling by extending the lifetime of the receptor ligand complex on the cell surface. In a mouse model of acute respiratory distress syndrome (ARDS), H8mb markedly improved survival. These results demonstrate that de novo designed receptor binders can enable dissection of co-receptor control of signaling dynamics, and the more stable and manufacturable H8mb provides routes to more developable therapeutic candidates.

  • Open Access

    The Significance of Angiopoietin Valency in Vascular Health and Disease

    by Yan Ting Zhao, Devon D. Ehnes, Julie Mathieu, Hannele Ruohola-Baker

    The Angiopoietin–Tie2 pathway is a key regulator of postnatal vascular maintenance and remodeling, regulating vascular barrier function and integrity. While the opposing roles of the ligands Angiopoietin-1 (Ang 1) and Angiopoietin-2 (Ang 2) have been recognized for decades, the structural mechanism governing their distinct signaling outputs has only recently been elucidated. As artificial intelligence and protein design continue to develop, emerging evidence suggests that ligand valency and receptor clustering are key determinants of Tie2 pathway activation and endothelial cell function; that is, “form follows function”. This review summarizes the latest discovery in the structural biology and signaling mechanism of the Tie2 pathway using protein design to decode the ligand–receptor interactions. Probing the underlying molecular basis of Tie2 offers new therapeutic opportunities for targeting diseases, featuring vascular dysfunctions such as sepsis, traumatic brain injury, acute respiratory diseases, chronic inflammation, and cancer. This also highlights the next generation of AI-designed protein therapeutics.


  • Open Access

    Designed Minibinders Rewire Receptor Signaling to Enable Functional Human Myogenic Reprogramming

    by Riya Keshri, Zachary Foreman, Phillip Barrett, Alexander J. Robinson, Gabriela Reyes, Ashish A. Phal, Aditya Krishnakumar, Ethan Narog, Melodie Chiu, Shruti Jain, et al.

    Sarcopenia, loss of muscle mass is a considerable health burden that demands immediate societal attention and calls for new regenerative strategies. Direct myogenic somatic cell reprogramming, a potential muscle regeneration method is constrained by an inability to control the signaling logic that governs cell fate. Here, we show that this barrier can be overcome using AI-designed receptor modulators. Screening de novo minibinders, we identify a synthetic protein cocktail, C6-DPC, that drives efficient human fibroblast-to-muscle transdifferentiation with robust structural and metabolic maturation. C6-DPC reprograms extracellular signaling by activating pro-myogenic FGFR1/2-c pathways while suppressing anti-myogenic inputs through ALK1 and TGFBR2; targeted depletion of ALK1 is sufficient to lower the reprogramming barrier. Inflammatory signaling via gp130 emerges as a dominant checkpoint, and its inhibition further enhances fibroblast-to-muscle conversion. C6-DPC treated engineered tissues generate high twitch and tetanic forces in both wild-type and dystrophin-deficient human cells. These findings demonstrate programmable control of receptor signaling as a strategy to direct myogenic cell fate and generate functional human muscle, providing a foundation for regenerative approaches to muscle loss and disease.

  • Open Access

    Epigenetic control of PDX1 and NGN3 by a computationally designed PRC2 inhibitor enforces pancreatic endocrine differentiation from pluripotent stem cells

    by Vincenzo Cirulli, Laura Crisa, Shiri Levy, Daniel Mar, Karol Bomsztyk, Stephanie Battle, Sina Gharib, Cecilia Lpez-Martinez, Patrick McGrath, Julie Mathieu, et al.

    Directed differentiation of pluripotent stem cells (PSCs) into pancreatic islets is a cornerstone strategy for diabetes cell therapy. This process relies on growth factor–driven activation of core transcriptional regulators, notably PDX1 and NGN3, to restrict the multi-lineage potential of definitive endoderm to pancreatic progenitors and endocrine cell types. Yet differentiation efficiency and lineage fidelity vary markedly across PSC lines. Here, we demonstrate that a dominant constraint is persistent Polycomb Repressive Complex 2 (PRC2)–mediated epigenetic repression at the PDX1 and NGN3 loci, limiting endocrine specification despite inductive signaling. To directly test whether chromatin states at the PDX1 and NGN3 loci gate developmental competence, we deployed a computationally engineered epigenetic effector (EBdCas9) to transiently and sequentially remove H3K27me3 at those loci during defined developmental windows. Targeted epigenetic resolution robustly enhanced endocrine lineage commitment and accelerated β-cell differentiation across genetically diverse PSC lines. In contrast, direct transcriptional activation with VP64dCas9 increased PDX1 and NGN3 expression but did not improve differentiation outcomes. Integrated cell population studies and genome-wide chromatin and transcriptomic analyses reveal that PRC2-targeted remodeling preferentially activates endocrine gene networks while limiting progenitor expansion and lineage-inappropriate programs. These findings establish that gene-targeted manipulation of PRC2-mediated repression at PDX1 and NGN3 can be used to control cell lineage competence. Collectively, our study reframes variability in PSC differentiation as a failure of epigenetic resolution rather than transcriptional insufficiency and introduces locus-specific chromatin remodeling as a generalizable strategy to enforce developmental fidelity.


  • Top Cited Papers
    Open Access

    Soluble Notch agonist enables human ameloblast maturation and enamel-like tissue formation for tooth regeneration

    by Anjali P. Patni, Rubul Mout, Ammar Alghadeer, Rachel H. Moore, Samera Nademi, Brandon J. Ausk, Philippe Huber, Riya Keshri, Mary Regier, Robert A. Cornell, et al.

    Enamel, the hardest mineralized material in the human body, protects the underlying living tissues, the dentin and pulp of the tooth. However, over 90% of adults have lost or damaged enamel and cannot regenerate the protective structure due to lack of enamel-producing cells, ameloblasts. iPSC-derived secretory Ameloblasts (isAM) have promise in future regenerative dentistry. Today, it is not known why iAM maturation requires intimate contact with the dentin-producing cell type, odontoblast. Here, we reveal that one of the critical signaling ligands emanating from odontoblasts for ameloblast maturation is Delta, the ligand for Notch receptor. We showed that our designed, soluble Notch agonist can induce iAM organoid maturation in an unprecedented manner, without interactions with odontoblast layer. Notably, soluble Notch agonist induces the iAM maturation to a novel, WDR72-positive mature secretory AM stage (ismAM) in our ameloblast organoid model. When transplanted under the kidney capsule of NOD-SCID mice, these ismAM organoids generated enamel-like calcified material, as confirmed by microCT analysis, marking the first demonstration that Notch-activated iAM organoids can form such tissue in vivo. This novel maturation procedure enabled us to analyze the specific requirements of DLX3 function in ameloblasts, independent of its known function in odontoblasts. We now show that DLX3, a gene associated with Amelogenesis Imperfecta, is required on a cell-autonomous manner in human ameloblasts for the expression of Enamelin, MMP20, and WDR72, a role not previously demonstrated in mouse models.


  • Open Access

    Natural Genetic Variation Impacts Stress-Induced Quiescence and Regeneration in Response to Rapamycin

    by Sahiti Peddibhotla, Miriam Gonzaga, Tricia Zhang, Yasha Goel, Jun Sun, Benjamin R. Harrison, Daniel E. L. Promislow, Hannele Ruohola-Baker

    In response to ionizing radiation (IR), both adult and cancer stem cells enter reversible cell cycle arrest at the G1/S transition to evade apoptosis and subsequently re-enter the cell cycle to regenerate damaged tissue. Entry into and exit from this arrest, known as “quiescence,” is governed by the inhibition of mTORC1. The pharmacological suppression of mTORC1 with rapamycin prevents quiescent stem cells from re-entering the cell cycle and impairs tissue regeneration. Rapamycin holds great therapeutic promise in preventing tumor regrowth from dormant cancer stem cells. Yet the extent to which genetic background impacts the known variation in the pharmacological response of rapamycin remains unknown. Here, we show that natural genetic variation across the Drosophila Genetics Reference Panel (DGRP) drives substantial differences in the rapamycin-mediated suppression of post-IR quiescence and regeneration. To define the basis of this differential sensitivity, we examined mitochondrial turnover and DNA damage repair—processes controlling IR-induced dormancy. Our analyses reveal that variation in rapamycin sensitivity is more strongly associated with differences in mitochondrial dynamics than with DNA damage response following radiation. Together, these findings demonstrate that genetic background is a critical determinant of rapamycin efficacy and identify mitochondrial regulation as a key mechanism underlying differential therapeutic response.

  • Open Access

    Templating and confining calcium phosphate mineralization within designed protein assemblies

    by Le Tracy Yu, Xinqi Li, Harley Pyles, Anjali P Patni, Andrew J. Borst, Neville P. Bethel, Paul S. Kwon, Connor Weidle, Ryan Daniel Kibler, Kenneth D. Carr, et al.

    Bone formation involves the deposition of ordered hydroxyapatite (HAp) on collagen fibrils, but the underlying molecular mechanisms remain largely unresolved, limiting the design of protein-apatite hybrid materials. Here we show that computationally designed de novo proteins can template and confine HAp mineralization. We design C3-symmetric oligomers with inner surfaces chemically complementary to the HAp {010} facet, and assemble these through additional interfaces into D3 oligomers, one-dimensional nanotubes, and two-dimensional arrays. Electron microscopy revealed templated mineralization and confinement at each hierarchical level, with mineral shape guided by the underlying protein architecture. Conversion of an initially formed amorphous phase to HAp is driven by the designed protein-mineral interface. Our results establish a framework for programmable protein-guided mineralization, providing a foundation for next-generation hybrid materials.


  • Top Cited Papers
    Open Access

    Improved protein binder design using β-pairing targeted RFdiffusion

    by Isaac Sappington, Martin Toul, David S. Lee, Stephanie A. Robinson, Inna Goreshnik, Clara McCurdy, Tung Ching Chan, Nic Buchholz, Buwei Huang, Dionne Vafeados, et al.

    Designing proteins that bind with high affinity to hydrophilic protein target sites remains a challenging problem. Here we show that RFdiffusion can be conditioned to generate protein scaffolds that form geometrically matched extended β-sheets with target protein edge β-strands in which polar groups on the target are complemented with hydrogen bonding groups on the design. We use this approach to design binders against edge-strand target sites on KIT, PDGFRɑ, ALK-2, ALK-3, FCRL5, NRP1, and α-CTX, and obtain higher (pM to mid nM) affinities and success rates than unconditioned RFdiffusion. Despite sharing β-strand interactions, designs have high specificity, reflecting the precise customization of interacting β-strand geometry and additional designed binder-target interactions. A binder-KIT co-crystal structure is nearly identical to the design model, confirming the accuracy of the design approach. The ability to robustly generate binders to the hydrophilic interaction surfaces of exposed β-strands considerably increases the range of computational binder design.


  • Open Access

    Rapamycin Differentially Impacts Germline Stem Cell Quiescence Across Diverse Genetic Backgrounds of Drosophila Melanogaster

    by Sahiti Peddibhotla, Miriam Gonzaga, Tricia Zhang, Yasha Goel, Jun Sun, Benjamin R. Harrison, Daniel E. L. Promislow, Hannele Ruohola-Baker

    In response to ionizing radiation, stem cells enter a state of temporary quiescence, safeguarding the stem cell pool for tissue regeneration. Quiescence requires the inhibition of mTORC1, a kinase complex that promotes growth and suppresses autophagy, and cell cycle re-entry requires the reactivation of mTORC1. The pharmacological inhibition of mTORC1 in quiescent stem cells by rapamycin prevents cell cycle re-entry and subsequent tissue regeneration. It is well established that pharmacological responses can vary across genetic backgrounds, however, the extent to which genetic variation can impact the quiescence response to rapamycin is unclear. Here, we tested the sensitivity of stem cell quiescence to rapamycin in different genetic backgrounds within the Drosophila Genetic Reference Panel. These analyses revealed substantial variation across different genetic backgrounds, indicating that genetic variation can modulate drug-induced effects on stem cell dynamics. Our analyses suggest that mitophagy, rather than DNA damage response, is associated with the persistence of quiescence and delayed tissue regeneration by rapamycin. This work underscores the critical role of genetic background in determining drug efficacy, highlighting important implications for the therapeutic application of rapamycin.

  • Open Access

    High-Throughput De Novo Protein Design Yields Novel Immunomodulatory Agonists

    by Mohamad Abedi, Marc Expòsit, Brian Coventry, Divij Mathew, Shruti Jain, Aditya Krishnakumar, Inna Goreshnik, Sophie L. Gray-Gaillard, Margaret Lunn-Halbert, Ta-Yi Yu, et al.

    Cytokines regulate cell behavior by bringing together specific receptor subunits to trigger downstream signaling. Designed molecules that bring together non-natural receptor pairs could have novel signaling responses and cell specificities. We present a high-throughput de-novo design approach to create novel cytokines by generating and fusing pairs of computationally designed binders. By combining 33 designed receptor-binding domains, we generated over a thousand potential de novo designed “Novokines”, of which 75 activated pSTAT signaling in peripheral blood mononuclear cells. We characterized 18 of these, including new pairings of established common receptors, cross-family pairings such as TrkA-γcommon, and a series of pairings with interferon receptor-1 (IFNAR1), revealing that IFNAR1 can function as a versatile common receptor similar to γcommon or βcommon. We identify novokines that drive monocyte proliferation, T cell survival and CD4 + T cell-specific proliferation. Our framework provides a blueprint for expanding the understanding of cytokine signaling and generating novel therapeutic proteins.